Compare · SNN vs STE
SNN vs STE
Side-by-side comparison of Smith & Nephew SNATS Inc. (SNN) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SNN and STE operate in Industrial Specialties (Health Care), so they compete in similar markets.
- STE is the larger of the two at $20.73B, about 1.6x SNN ($13.01B).
- Over the past year, SNN is up 2.5% and STE is down 12.6% - SNN leads by 15.1 points.
- STE has been more active in the news (32 items in the past 4 weeks vs 11 for SNN).
- SNN has more recent analyst coverage (23 ratings vs 16 for STE).
- Company
- Smith & Nephew SNATS Inc.
- STERIS plc (Ireland)
- Price
- $30.61-0.81%
- $212.19-0.03%
- Market cap
- $13.01B
- $20.73B
- 1M return
- +1.22%
- -1.07%
- 1Y return
- +2.48%
- -12.59%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 11
- 32
- Recent ratings
- 23
- 16
Smith & Nephew SNATS Inc.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest SNN
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- Smith & Nephew downgraded by Kepler
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- Smith+Nephew launch next generation LEAF™ Patient Monitoring System – an innovative pressure injury prevention platform delivering proven clinical impact
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- A Reno Biotech Just Rang the Nasdaq Bell — Here's Why the Whole Regenerative-Medicine Tape Is Worth Watching
- SEC Form SD filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
Latest STE
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 365 units of Ordinary Shares, decreasing direct ownership by 0.97% to 37,079 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 64 units of Ordinary Shares, decreasing direct ownership by 1% to 6,259 units (SEC Form 4)
- Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 239 units of Ordinary Shares, decreasing direct ownership by 2% to 12,452 units (SEC Form 4)
- SVP & GM, AST Kohler Kenneth E covered exercise/tax liability with 184 units of Ordinary Shares, decreasing direct ownership by 2% to 11,482 units (SEC Form 4)
- SVP & Chief HRO Fraser Mary Clare covered exercise/tax liability with 311 units of Ordinary Shares, decreasing direct ownership by 2% to 14,316 units (SEC Form 4)
- President and CEO Carestio Daniel A covered exercise/tax liability with 2,619 units of Ordinary Shares, decreasing direct ownership by 4% to 69,964 units (SEC Form 4)
- Sr. Vice Pres., CFO Burton Karen L covered exercise/tax liability with 190 units of Ordinary Shares, decreasing direct ownership by 1% to 13,274 units (SEC Form 4)
- SEC Form 144 filed by STERIS plc (Ireland)
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam was granted 4,359 units of Ordinary Shares and covered exercise/tax liability with 247 units of Ordinary Shares, increasing direct ownership by 12% to 37,444 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato was granted 750 units of Ordinary Shares and covered exercise/tax liability with 41 units of Ordinary Shares, increasing direct ownership by 13% to 6,323 units (SEC Form 4)